GGrantIndex
← Leaderboards

Craig J Burd

Ohio State University

$3,860,523
Attributed
$3,860,523
Total exposure
3
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $707.1K · FY201325
$1M$750K$500K$250K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$3,860,523 · 3

By mechanism

R01$3,131,062 · 2
R00$729,461 · 1

Top collaborators

No co-investigators on record.

Most similar at Ohio State University

Same institution · by research overlap

Others in their field

Top investigators on “Malignant Neoplasms

Research focus

Malignant NeoplasmsWomanExhibitsSignal TransductionEstrogensPlayExposure ToClinical ResearchMediatingGeneticMolecularLinkMouse ModelBiologyHormonesMalignant Breast NeoplasmBiologicalAnimal ModelBiochemicalBreastBisphenol AEpigenetic ProcessEventEndocrine Disruptors

Grant awards (12)

Estrogen receptor beta is a targetable melanoma tumor suppressor$356,540
R01 · FY2025 · CA · contact PI
Defining the role of in utero estrogenic endocrine disruption on mammary gland stiffness and breast cancer risk$350,530
R01 · FY2025 · ES · contact PI
Defining the role of in utero estrogenic endocrine disruption on mammary gland stiffness and breast cancer risk$350,747
R01 · FY2024 · ES · contact PI
Estrogen receptor beta is a targetable melanoma tumor suppressor$333,894
R01 · FY2024 · CA · contact PI
Defining the role of in utero estrogenic endocrine disruption on mammary gland stiffness and breast cancer risk$345,531
R01 · FY2023 · ES · contact PI
Estrogen receptor beta is a targetable melanoma tumor suppressor$344,926
R01 · FY2023 · CA · contact PI
Estrogen receptor beta is a targetable melanoma tumor suppressor$356,359
R01 · FY2022 · CA · contact PI
Defining the role of in utero estrogenic endocrine disruption on mammary gland stiffness and breast cancer risk$346,031
R01 · FY2022 · ES · contact PI
Defining the role of in utero estrogenic endocrine disruption on mammary gland stiffness and breast cancer risk$346,504
R01 · FY2021 · ES · contact PI
Chromatin Dynamics of Endocrine Disruptor Compounds on Estrogen Receptor Function$237,246
R00 · FY2015 · ES · contact PI
Chromatin Dynamics of Endocrine Disruptor Compounds on Estrogen Receptor Function$243,215
R00 · FY2014 · ES · contact PI
Chromatin Dynamics of Endocrine Disruptor Compounds on Estrogen Receptor Function$249,000
R00 · FY2013 · ES · contact PI